[Edaily Reporter Kim Seung-kwon ] #3billion Inc., an AI-based genetic diagnostics company, has achieved both revenue growth and improved profitability while increasing its investment in research and development (R&D).

3billion Inc. announced on the 13th that it recorded cumulative consolidated revenue of 11.4 billion won for the first three quarters of this year. This represents a 45.1% increase compared to the same period last year. Third-quarter revenue totaled 4.2 billion won, up 30.0% year-over-year, while the operating loss narrowed to 1.2 billion won, a 25.9% decrease from the previous quarter.

Cumulative ordinary R&D expenses for the same period totaled 3.4 billion won, an increase of approximately 36% compared to the same period last year. Despite this, the cumulative operating loss ratio improved by 21.6 percentage points, from 61.8% to 40.2%. Cumulative net income for the third quarter totaled 2.5 billion won.

These results were driven by the company’s core business: genetic diagnostic services for rare diseases. Cumulative revenue for this business in the third quarter reached 9.9 billion won, a 46.8% increase year-over-year, accounting for 87.2% of total cumulative revenue. Overseas revenue totaled approximately 7.8 billion won, accounting for 68.7% of cumulative revenue. The company provides diagnostic services based on whole-exome sequencing (WES) and whole-genome sequencing (WGS), as well as the AI mutation interpretation software “GEBRA.” GEBRA is currently used by medical institutions in over 40 countries.

New business ventures have also begun generating revenue. “3B-NEO,” a newborn genomic screening service launched in overseas markets last June, generated its first revenue in the third quarter. In the Philippines, the company secured consecutive contracts for the first and second phases of a public sector pilot project. This initiative supports genome-based confirmatory testing for newborns who showed abnormal findings in initial screening tests. In the Dominican Republic, the company signed a supply contract with a local medical institution.

3billion Inc. is also expanding its business into new drug development by leveraging diagnostic data. As of the end of the third quarter, the company had accumulated approximately 118,000 patient genomic data sets. By combining this data with phenotypic data—such as symptoms—the company is refining its AI mutation interpretation model and expanding the scope of test automation. This month, the company signed a joint research agreement with DeepLife, a French AI-driven new drug development firm. The two companies plan to identify therapeutic targets based on patient genomes and analyze the mechanisms of action of these targets using DeepLife’s AI-powered virtual cell platform, “TwinCell,” to inform the design of drug candidates.

Kim Chang-won, CEO of 3billion Inc., said, “These results are significant because they demonstrate that we have increased revenue and reduced the burden of operating losses while expanding R&D investment to strengthen our diagnostic capabilities and advance AI-driven drug discovery.”